General Electric's GE Healthcare unit is partnering with Ontario's economic development authority and the not-for-profit Centre for Commercialization of Regenerative Medicine in Toronto to build a $28.3 million center that will provide cell therapy companies with facilities and expertise to help establish manufacturing processes that can produce the large cell numbers required for clinical and commercial use.
Advertised biotechnology and pharmaceutical sector jobs in the job databases tracked by Nature Biotechnology during the first quarter of 2016 are shown in Tables 1 and 2. Other downsizings within the life science industry are shown in Table 3 . Cut 25% of workforce in all major departments as its hypercholesterolemia treatment Juxtapid (lomitapide) faces increased competition in the US. Ariad Pharmaceuticals~9
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Reduced headcount by 19% to invest in the growth potential of leukemia drug Iclusig (ponatinib) and brigatinib, which is in a pivotal phase 2 trial to treat non-small-cell lung cancer. OncoGenex Pharmaceuticals
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Reduced headcount by 27% to focus on reaching several near-term clinical milestones for custirsen and apatorsen. Opexa Therapeutics
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Cut 28% of workforce to focus on completing the phase 2b Abili-T trial of Tcelna (imilecleucel-T) to treat secondary progressive multiple sclerosis. Sequenom 110 Reduced headcount to 390 to focus on women's health and will look for commercialization partners for its cancer liquid biopsy assay. Will close its laboratory in Research Triangle Park, NC, and consolidate those operations in San Diego.
